Positive interim data from Phase II study of SARS-CoV-2 neutralising antibodies (LY-CoV016 and LY-CoV555) in the outpatient setting

An interim analysis of the BLAZE-1 clinical trial shows combination therapy with neutralising antibodies in people with recently diagnosed mild-to-moderate COVID-19 illness reduced viral load at day 11 (primary endpoint; no data presented).

SPS commentary:

Lilly intends to submit a request to the US FDA for Emergency Use Authorization (EUA) for the combination therapy in patients with mild-to-moderate COVID-19 in November 2020.

Biospace Inc.